

SPW


PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# TRANSMITTAL FORM

to be used for all correspondence after initial filing)

<b>Application Number</b>	10/049,871		
	<b>Filing Date</b>	October 3, 2003	
	<b>First Named Inventor</b>	Yanina ROZENBERG et al.	
	<b>Group Art Unit</b>	1632	
	<b>Examiner Name</b>	Unassigned	
<b>Total Number of Pages in This Submission</b>	5	<b>Attorney Docket Number</b>	38147-0039

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): <b>PTO/SB/08A w/ 39 references</b>
<b>Remarks</b>		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

<b>Firm or Individual name</b>	Paul M. Booth, Reg. No. 40,244
<b>Signature</b>	Lara Z. WTD for Paul M. Booth (Reg. No. 51,019)
<b>Date</b>	June 25, 2004

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <input type="text"/>			
<b>Typed or printed name</b>			
<b>Signature</b>		<b>Date</b>	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. DC142800v1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

New Attorney Docket No.: 38147-0039

Applicant: Yanina ROZENBERG *et al.*

Confirmation No.: 2364

Appl. No.: 10/049,871 (371 of PCT/US00/22619) Group Art Unit: 1632

Filing Date: October 3, 2003

Examiner: To Be Assigned

Title: TARGETED ARTIFICIAL GENE DELIVERY

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

To comply with Applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97, Applicants submit herewith on attached Form PTO/SB/08A, a listing of documents known to Applicants. A copy of each of the listed documents is being submitted to comply with the provisions of 37 C.F.R. §§1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action that would be appropriate to antedate or otherwise remove as a competent reference any document that is determined to be a *prima facie* prior art reference against the claims of the present application.


This Information Disclosure Statement is being filed in compliance with 37 CFR §1.97(b) prior to the mailing date of the first Office Action. Therefore, Applicants believe that

no fee is required at this time. However, the Commissioner is hereby authorized to charge any deficiency or to credit any overpayment to Deposit Account No. 08-1641.

Applicants respectfully request that the listed documents be considered by the Examiner and made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,


Date: June 21, 2004

By:   
Paul M. Booth  
Attorney for Applicant  
Registration No. 40,244

HELLER EHRMAN WHITE &  
MCAULIFFE LLP  
1666 K Street, N.W., Suite 300  
Washington, DC 20006-1228  
Telephone: (202) 912-2000  
Facsimile: (202) 912-2020  
Customer No. 26633

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)				Application Number	10/049,871
				Filing Date	October 3, 2003
				First Named Inventor	Yanina Rozenberg <i>et al.</i>
				Art Unit	1632
				Examiner Name	To Be Assigned
Sheet	1	of	2	Attorney Docket Number	38147-0039 (271010-473)



U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US-5,631,018	05-20-1997	Zalipsky <i>et al.</i>	
	2.	US-5,661,022	08-26-1997	Kotani <i>et al.</i>	
	3.	US-5,665,577	09-09-1997	Sodroski <i>et al.</i>	
	4.	US-5,686,279	11-11-1997	Finer <i>et al.</i>	
	5.	US-5,766,625	06-16-1998	Schreier <i>et al.</i>	
	6.	US-5,780,221	07-14-1998	Schumacher <i>et al.</i>	
	7.	US-5,916,803	06-29-1999	Sedlacek <i>et al.</i>	
	8.				
	9.				
	10.				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	1.	WO 91/19798	12-26-1991	Sodroski <i>et al.</i>		
	2.	WO 97/12622	04-10-1997	Verma <i>et al.</i>		
	3.	WO 97/40854	11-06-1997	Summerton <i>et al.</i>		
	4.	WO 98/12314	03-26-1998	Trono <i>et al.</i>		
	5.					
	6.					
	7.					
	8.					
	9.					

Examiner Signature	Date Considered
--------------------	-----------------

\*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/049,871
		Filing Date	October 3, 2003
		First Named Inventor	Yanina Rozenberg <i>et al.</i>
		Art Unit	1632
		Examiner Name	To Be Assigned
		Attorney Docket Number	38147-0039 (271010-473)
Page 1 of 2	2	of	2

## NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	1.	ANDERSON, <i>Nature</i> , 392 (6679 Suppl): 25-30 (1998).	
	2.	BOUSSIF <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 92:7297-7301 (1995).	
	3.	BOXUS <i>et al.</i> , <i>Bioorganic and Medicinal Chemistry</i> , 6:1577-1595 (1998).	
	4.	CHOI <i>et al.</i> , <i>Bioconjugate Chem.</i> , 9:708-718 (1998).	
	5.	FASBENDER <i>et al.</i> , <i>J. Biol. Chem.</i> , 272:6479-6489 (1997).	
	6.	HAUBNER <i>et al.</i> , <i>Angew. Chem. Int. Ed. Engl.</i> , 36:1374-1389 (1997).	
	7.	KAGAWA <i>et al.</i> , <i>J. Biol. Chem.</i> , 246, 17:5477-5487 (1971).	
	8.	KIEBER-EMMONS <i>et al.</i> , <i>Current Opinion in Biotechnology</i> , 8:432-441 (1997).	
	9.	KIRPOTIN <i>et al.</i> , <i>FEBS Letters</i> , 388:115-118 (1996).	
	10.	KWOH <i>et al.</i> , <i>Biochimica et Biophysica Acta</i> , 1444:171-190 (1999).	
	11.	MEYER <i>et al.</i> , <i>FEBS Letters</i> , 421:61-64 (1998).	
	12.	MEYER <i>et al.</i> , <i>J. Biol. Chem.</i> , 372, 25:15621-15627 (1998).	
	13.	MINOURA, <i>Langmuir</i> , 14:2145-2147 (1998).	
	14.	NAKANISHI <i>et al.</i> , <i>J. of Controlled Release</i> 54:61-68 (1998).	
	15.	PAPAHADJOPOULOS <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 15: 11460-4 (1991).	
	16.	PAPISOV, <i>Adv. Drug Delivery Review</i> , 32:119-138 (1998).	
	17.	PAULETTI <i>et al.</i> , <i>Adv. Drug Delivery Review</i> , 27:235-256 (1997).	
	18.	SAPHIRE <i>et al.</i> , <i>J. Biol. Chem.</i> , 273, 45:29764-29769 (1998).	
	19.	SCHNIERLE AND GRONER, <i>Gene Therapy</i> , 3:1069-73 (1996).	
	20.	SUBBARAO <i>et al.</i> , <i>Biochemistry</i> , 26:2964-2972 (1987).	
	21.	TANG <i>et al.</i> , <i>Biochem. Biophys. Res. Comm.</i> , 242:141-145 (1998).	
	22.	VERMA <i>et al.</i> , <i>Nature</i> , 389: 239-42 (1997).	
	23.	VIEWEG <i>et al.</i> , <i>Cancer Research</i> , 55: 2366-2372 (1995).	
	24.	VINOGRADOV <i>et al.</i> , <i>Bioconjugate Chem.</i> , 9:805-812 (1998).	
	25.	WOODLE <i>et al.</i> , "Small Molecule Ligands for Targeting Long Circulating Liposomes", <i>Long Circulating Liposomes: Old Drugs, New Therapeutics</i> , pp. 287-295, Ed. by Woodle and Storm, Springer-Verlag and Landes Bioscience (1998).	
	26.	WYMAN <i>et al.</i> , <i>Biochemistry</i> , 36:3008-3017 (1997).	
	27.	ZANTA <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 96:91-96 (1999).	
	28.	ZELPHATI <i>et al.</i> , <i>Gene Therapy</i> , 5:1272-1282 (1998).	

Examiner Signature	Date Considered
--------------------	-----------------

\*Examiner: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.